สารบัญ

Contents
MENU

MALAYAN KRAIT ANTIVENIN

Thai name เซรุ่มแก้พิษงูสมิงคลา (SERUM KAE PHIT NGU TAPSAMINGKHLA)

Category Passive immunizing agent.

          Malayan Krait Antivenin is a sterile preparation containing the specific antitoxic globulins from immunized animals. It has the power of neutralizing the Malayan krait (Bungarus candidus) venom.

          The antivenin, reconstituted if necessary as stated on the label, complies with the requirements stated under Antisera, with the following modifications.

Description Colourless or slightly yellowish brown transparent liquid. Freeze-dried antivenin consists of solid exhibiting the characteristic structure of a freezedried solid, light cream in colour.

Expiration date; Warning See under Cobra Antivenin, p. 232.

Labelling Complies with the “General Information for Antisera”, p. 225. In addition the label on the container states (1) the number in mg of reference Malayan krait venom neutralized by a specified quantity of the antivenin; (2) the recommended human dose; (3) the nature of the preparation, e.g. natural serum or purified immunoglobulin or treated immunoglobulin and, if purified or treated, the nature of the process.

Identification Specifically neutralizes the Malayan krait venom, rendering it harmless to susceptible animals. The assay may serve as an identification test.

Assay Each ml contains sufficient antitoxic globulins to neutralize the amount of the Malayan krait venom stated on the label when determined by the “Biological Assay of Cobra Antivenin” (Appendix 15.2.7); use the Malayan krait test venom for determining its capacity to neutralize the lethal effect.

Usual dose Initial dose 50 ml of liquid or freeze-dried Malayan Krait Antivenin (after reconstitution by accompanying diluent) should be given by slow intravenous infusion (approximately 2 ml per minute). During the observation period, subsequent doses can be given every 12 hours according to the clinical symptoms.

MONOGRAPHS • MALAYAN KRAIT ANTIVENIN
view 1,437 ผู้เข้าชม / View
หมายเหตุ / Note : TP II 2011 PAGE 233-234